全文获取类型
收费全文 | 78788篇 |
免费 | 7755篇 |
国内免费 | 3382篇 |
专业分类
耳鼻咽喉 | 128篇 |
儿科学 | 4135篇 |
妇产科学 | 379篇 |
基础医学 | 6256篇 |
口腔科学 | 566篇 |
临床医学 | 8307篇 |
内科学 | 13813篇 |
皮肤病学 | 681篇 |
神经病学 | 1906篇 |
特种医学 | 1887篇 |
外国民族医学 | 7篇 |
外科学 | 28419篇 |
综合类 | 10166篇 |
现状与发展 | 16篇 |
一般理论 | 5篇 |
预防医学 | 2388篇 |
眼科学 | 1292篇 |
药学 | 3957篇 |
33篇 | |
中国医学 | 3086篇 |
肿瘤学 | 2498篇 |
出版年
2024年 | 97篇 |
2023年 | 1492篇 |
2022年 | 1652篇 |
2021年 | 3540篇 |
2020年 | 3228篇 |
2019年 | 3507篇 |
2018年 | 3381篇 |
2017年 | 3142篇 |
2016年 | 3081篇 |
2015年 | 3026篇 |
2014年 | 5141篇 |
2013年 | 5859篇 |
2012年 | 3985篇 |
2011年 | 4753篇 |
2010年 | 4160篇 |
2009年 | 4074篇 |
2008年 | 4170篇 |
2007年 | 4269篇 |
2006年 | 4150篇 |
2005年 | 3579篇 |
2004年 | 2970篇 |
2003年 | 2522篇 |
2002年 | 2070篇 |
2001年 | 1791篇 |
2000年 | 1415篇 |
1999年 | 1109篇 |
1998年 | 996篇 |
1997年 | 862篇 |
1996年 | 758篇 |
1995年 | 697篇 |
1994年 | 754篇 |
1993年 | 459篇 |
1992年 | 563篇 |
1991年 | 437篇 |
1990年 | 285篇 |
1989年 | 286篇 |
1988年 | 281篇 |
1987年 | 206篇 |
1986年 | 165篇 |
1985年 | 185篇 |
1984年 | 160篇 |
1983年 | 85篇 |
1982年 | 111篇 |
1981年 | 101篇 |
1980年 | 68篇 |
1979年 | 69篇 |
1978年 | 62篇 |
1977年 | 52篇 |
1976年 | 44篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 468 毫秒
1.
2.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献
3.
4.
5.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献
6.
7.
8.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
9.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
10.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献